GeneTex knockout/knockdown validated antibodies

Antibodies are essential tools for both basic and clinical research. However, there has been growing distrust of commercially available antibodies with regard to specificity and performance variability. As a result, the research community and funding agencies have demanded that antibody suppliers increase their efforts to more thoroughly validate these reagents. One approach to address this is through knockdown or knockout of the target protein by RNAi- or CRISPR-mediated technologies.

In support of this goal, GeneTex is conducting knockdown-based validation as a fundamental component of its antibody quality assurance process. To date, GeneTex has evaluated over 500 products covering research topics such as apoptosis, metabolism, epithelial–mesenchymal transition and neurodegenerative diseases. The company will continue to expand these efforts in the future.

All GeneTex antibodies that have passed the KO/KD test will be labelled with the KO/KD validated icon.​